RAMM Pharma Commences Epifractán™ Sales through Peruvian Pharmacies and Scales up Exports to Brazil
08 oct. 2020 07h53 HE
|
RAMM Pharma Corp.
TORONTO, Oct. 08, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma Announces Approval and Registration of Epifractán™ 2% by Peru’s Ministry of Health
16 juil. 2020 08h00 HE
|
RAMM Pharma Corp.
TORONTO, July 16, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma Announces Approval and Registration of Epifractán™ 5% by Peru’s Ministry of Health and Enters Distribution Agreement to Supply Pharmacies in Peru
09 juil. 2020 07h59 HE
|
RAMM Pharma Corp.
TORONTO, July 09, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma announces its quarter financial results for Q2 2020
29 juin 2020 17h01 HE
|
RAMM Pharma Corp.
TORONTO, June 29, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma Corp. Announces Intention to Commence Normal Course Issuer Bid
15 avr. 2020 11h55 HE
|
RAMM Pharma Corp.
TORONTO, April 15, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), announces its intention to commence a normal course...
RAMM Pharma Corp. Announces Postponement of Filing of Interim Financial Statements
30 mars 2020 09h36 HE
|
RAMM Pharma Corp.
TORONTO, March 30, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma Corp. Receives Federal Approval and Registration of XALEX™ 10 (cannabidiol) Oral Solution
26 mars 2020 14h01 HE
|
RAMM Pharma Corp.
TORONTO, March 26, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma Corp. Provides Details on Operational Activities to Support COVID-19 Medical Response Effort & Corporate Update
23 mars 2020 15h06 HE
|
RAMM Pharma Corp.
TORONTO, March 23, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma Corp. to Acquire NettaLife, a Leading Developer of Cannabis-Based Products for Pets and Large Animals
25 févr. 2020 07h30 HE
|
RAMM Pharma Corp.
TORONTO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma Corp. Welcomes Legalization of Medical Cannabis in Brazil
05 déc. 2019 09h23 HE
|
RAMM Pharma Corp.
TORONTO, Dec. 05, 2019 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...